Changes in gastric ECL cells and parietal cells after long-term administration of high-dose omeprazole to patients with Barrett's esophagus

Tokai Journal of Experimental and Clinical Medicine

Volumn 30, Issue 2, 2005, Pages 117-121

  Nishi, Takayuki ^a,b,c   Makuuchi, Hiroyasu ^a   Weinstein, Wilfred M ^b  

^a TOKAI UNIVERSITY   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Barrett's esophagus; Enterochromaffin like cell; Hypergastrinemia; Omeprazole; Parietal cell; Ranitidine

Indexed keywords

GASTRIN; OMEPRAZOLE; RANITIDINE;

ARTICLE; BARRETT ESOPHAGUS; CELL COUNT; CELL HYPERPLASIA; CONTROLLED STUDY; DIGESTIVE TRACT ENDOSCOPY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENDOSCOPIC BIOPSY; ENTEROCHROMAFFIN CELL; FEMALE; GASTRIN BLOOD LEVEL; HUMAN; HYPERGASTRINEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; STOMACH BIOPSY; STOMACH MUCOSA; STOMACH PARIETAL CELL; TREATMENT OUTCOME;

ANTI-ULCER AGENTS; BARRETT ESOPHAGUS; CELL COUNT; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROCHROMAFFIN CELLS; FEMALE; GASTRINS; GASTROSCOPY; HUMANS; HYPERPLASIA; MALE; OMEPRAZOLE; PARIETAL CELLS, GASTRIC; PROTON PUMPS; TIME FACTORS;

EID: 23944523537     PISSN: 03850005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Rolf Hakanson, Duan Chen, Frank Sundler, (edited by Leonard R. Johnson.) The ECL Cells. Physiology of the Gastrointestinal Tract. 3rd edition. Raven Press, New York. 1171-1184, 1994.
2. +) ATPase. Nature Mar 12: 290(5802): 159-61, 1981.
3. Walsh, J H. Role of gastrin as atrophic hormone. Digestion 47(Suppl.1): 11-16, 1990.
4. Carlsson, E, Larsson, H, Mattsson, H. Pharmacology and Toxicology of Omeplazole-with Special Reference on the Gastric Mucosa. Scand J Gastroenterol 118; 31-38, 1986.
5. Solcia, E, Bordi, C, Creutzfeldt, W. Mistopathological Classification of Nonantral Gastric Endocrine Growths in Man. Digention 41: 185-200, 1998.
6. Larsson, H, carlsson, E, Mattsson, H. Plasma Gastrin and Gastric Enterochromaffin-like Cell Activation and Proliferation. Gastroenterology. 90; 391-399, 1986.
7. Annibale, B, Aprile, M R, Ferraro, G. Relationship between fundic endocrine cells and gastric acid secretion in hypersecretory duodenal ulcer diseases Aliment Pharmacol Ther 12: 779-778, 1998.
8. Marie Daniele Diebold, Sylvia Richardson, Alain Duchateau Factors Influencing Corpus Argyrophil Cell Density and Hyperplasiain Reflux Esophagitis Patients Treated with Antisecretory Drugs and Controls Digestive Diseases and Sciences, Vol.43, No.8, 1629-1635, 1998.
9. Rolf Eissele, Gorik Brunner, Babette Simon, et al. Gastric Mucosa During Treatment With Lansoprazole: Helicobacter Pylori Is a Risk Factor for Argyrophil Cell Hyperplasia. Gastoroenterol. 112; 707-717, 1997.
10. Hirschowitz, B I, Haber, M M. Helicobacter Pylori effects on gastritis, gastin and enterochromaffin-like cells in Zollinger-Ellison syndrome and nonZollinger-Ellison syndrome acid hypersecretors treated with long-term lansoprazole. Aliment Pharmacol Ther; 15; 87-103, 2001.
11. Lamberts, R, Creutzfeldt, W, Struber, H G. Long term omeprazole therapy in peptic ulcer disease gastrine, endocrine cell growth, and gastritis. Gastroenterology. 104, 1356-1370, 1993.
12. Solcia, E, Rindi, G, Havu, N. Qualitative Studies of Gastric Endocrine Cells in Patients Treated Long-term with Omeprazale. Scand J Gastroenterol 24(Suppl. 166); 129-137, 1989.
13. Brunner, G. and Creutzfeldt, W. Omeprazale in the Long-term Management of Patients with Acid-related Diseases Resistant to Ranitidine. Scand. J. Gastroenterol 24(Suppl. 166); 101-105, 1989.
14. Lind T, Cederberg C, Olausson M, Olbe L. Related Articles, Links 24-hour intragastric acidity and plasma gastrin after omeprazole treatment and after proximal gastric vagotomy in duodenal ulcer patients. Gastroenterology Dec; 99(6): 1593-8, 1990.
15. Stolte M, Meining A, Seifert E, et al. Treatment with lansoplazole also induces hypertrophy of the parietal cells of the stomach. Pathol Res Pract 196(1): 9-13, 2000.